Treatment of exacerbations of chronic obstructive pulmonary disease with pristinamycin;Traitement des exacerbations de broncho-pneumopathie chronique obstructive (BPCO) par la pristinamycine

Revue des Maladies Respiratoires

Volumn 21, Issue 2 PART 1, 2004, Pages 261-271

  Leophonte P ^a   Chidiac, C ^b   Drugeon, H B ^c   Strabach, S ^d   Cabrillac Rives, S ^e   Chone, C ^e   Dellatolas, F ^e   Safran, C ^e  

^a SERVICE DE PNEUMOLOGIE   (France)

^b CROIX ROUSSE HOSPITAL   (France)

^c HÔTEL DIEU   (France)

^d Alios Conseil   (France)

^e SANOFI   (France)

Author keywords

Antibiotics; Chronic obstructive bronchitis; Pristinamycin; Respiratory infection

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; PENICILLIN G; PRISTINAMYCIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SENSITIVITY; EPIGASTRIC PAIN; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RESPIRATORY TRACT INFECTION; STOMACH PAIN; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

EID: 3042696642     PISSN: 07618425     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0761-8425(04)71284-x     Document Type: Article

References (22)

1. Société de Pneumologie de Langue Française: Actualisation des recommandations de la SPLF pour la prise en charge des BPCO. Rev Mal Respir 2003;20:4565-8.
2. Pauwels RA, Buist AS, Ma P, Jenkins CR, Hurd SS: GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive summary. Respir Care 2001;46:798-825.
3. Anthonisen NR, Manfreda J, Warren, Hersfield ES, Harding GKM, Nelson NA: Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196-204.
4. Agence Française de Sécurité Sanitaire des Produits de Santé: Antibiothérapie générale en pratique courante: exacerbation de bronchite chronique, novembre 2001. Consulté sur http://agmed.sante.gouv.fr.
5. Société de Pathologie Infectieuse de Langue Française: Conférence de Consensus. Faut-il traiter par antibiotiques les bronchites aiguës de l'adulte sain ou du bronchitique chronique non-insuffisant respiratoire? Par quelles molécules? Chez quel type de patients? Med Mal Infect 2000;30:565-80.
6. Antibiotiques. Agents antibactériens et antifongiques. A. Bryskier. Editions Ellipses. 1999.
7. Dictionnaire Vidal 2003. Monographie de Pyostacine®
8. Wilson R, Kubin R, Ballin I, Deppermann KM, Bassaris HP, Leophonte P, Schreurs AJ, Torres A, Sommerauer B: Five-day moxifloxacin therapy compared with 7-day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1999;44:501-13.
9. Guillemot D, Carbon C, Balkau B, Geslin P, Lecoeur H, Vauzelle-Kervroedan F, Bouvenot G, Eschwege E: Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA 1998;279:365-70.
10. Lêautez S, Raffi F: Antibiothérapie des infections respiratoires: traitement court versus traitement long. Antibiotiques 2000;2:143-8.
11. Committee for Proprietary Medicinal Products, the European Agency for the Evaluation of Medicinal Products: Note for guidance on evaluation of new anti-bacterial medicinal products, Londres avril 1997 (CPMP/EWP/558/95). Consulté sur http://www.emea.eu.int/en février 2003.
12. US Department of health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research: Guidance for Industry, Acute Bacterial Exacerbation of Chronic Bronchitis - Developing Antimicrobial Drugs for Treatment, draft guidance July 1998. Consulté sur http://www.fda.gov/ cder/guidance/index.htm en février 2003.
13. IMS/Dorema. Cumul Mobile Hiver 00/01.
14. Thalès. Cumul Mobile Annuel 00.
15. Trémolières F, Azarian R, Lebas FX: Efficacité et tolérance de deux formulations orales d'Augmentin® 1g/125mg deux fois par jour versus 500 mg/125 mg trois par jour dans les exacerbations aiguës de bronchire chronique. Étude multicentrique, comparative, randomisée, en double aveugle. Méd Mal Infect 2000;30:630-40.
16. Committee for Proprietary Medicinal Products (CPMP): Points to consider on switching between superiority and non-inferiority. Br J Clin Pharmacol 2001;52:223-8.
17. Sethi S, Murphy TF: Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review. Clin Microb Rev 2001; 14:336-63.
18. Gompertz S, O'Brien C, Bayley DL, Stockley RA: Changes in bronchial inflammation during acute exacerbations of chronic bronchitis. Eur respir J 2001;17:1112-9.
19. Stockley RA, O'Brien C, Pye P, Hill SL: Relationship of sputum color to nature of outpatient management of acute exacerbations of COPD. Chest 2000;117:1638-45.
20. Chodosh S, Schreurs A, Siami G, Barkman HW, Anzueto A, Shan M, Moesker H, Stack T, Kowalsky S: Efficacy of oral ciprofloxacin vs. clarithromycin for treatment of acute exacerbation of chronic bronchitis. Clin Infect Dis 1998;27:730-8.
21. Chodosh S, McCarthy J, Farkas S, Drehobl M, Tosiello R, Shan M, Aneiro L, Kowalsky S: Randomized, double blind study of ciprofloxacin and cefuroxime axetil for treatment of acute bacterial exacerbation of chronic bronchitis. Clin Infect Dis 1998;27:722-9.
22. Gaillat J, Courtois X: Analyse critique des études cliniques sur les exacerbations aiguës de bronchite chronique (EABC). Antibiotiques 2000;2:215-20.